Literature DB >> 7996062

Plasma neurotransmitters and cortisol in chronic illness: role of stress.

F Lechin1, B van der Dijs, A Lechin, B Orozco, M Lechin, S Báez, I Rada, G León, E Acosta.   

Abstract

We routinely measured plasma neurotransmitters and hormone levels in order to investigate the role of stress on many types of diseases. In this study, we present results obtained from patients with severe chronic diseases. The study sample consisted of 88 patients (asthmatics, ulcerative colitis, Crohn's disease, chronic active hepatitis, chronic relapsing hepatitis, multiple sclerosis, trigeminal neuralgia, systemic lupus erithematous, and rheumatoid arthritis), and their respective controls. Noradrenaline (NA), adrenaline (Ad), dopamine (DA), platelet-serotonin (pS), free-serotonin (fS), growth hormone (GH) and cortisol (CRT) were determined during both exacerbation and improvement periods. A profile compatible with uncoping stress disorder (raised NA-Ad-DA + fS + CRT as well as low pS and NA/Ad ratio) was found during exacerbation periods when compared with improvement, as seen in controls. However, during improvement periods the neurochemical profile remained significantly different from that of normal controls. The neurochemical plus hormonal plasma profiles registered in chronic illness, both during exacerbation and improvement periods, strongly suggest that an uncoping stress mechanism underlies diseases of these patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7996062

Source DB:  PubMed          Journal:  J Med        ISSN: 0025-7850


  9 in total

1.  Changes in neurotransmitters in multiple sclerosis.

Authors:  V P Barkhatova; I A Zavalishin; L Sh Askarova; V Kh Shavratskii; E G Demina
Journal:  Neurosci Behav Physiol       Date:  1998 Jul-Aug

2.  Allergen and ozone exacerbate serotonin-induced increases in airway smooth muscle contraction in a model of childhood asthma.

Authors:  Brian D Moore; Dallas Hyde; Lisa Miller; Emily Wong; Jessica Frelinger; Edward S Schelegle
Journal:  Respiration       Date:  2012-04-13       Impact factor: 3.580

3.  Basal endocrine status in African dietary iron overload.

Authors:  Lynette McNamara; Vanessa R Panz; Frederick J Raal; Janice Paiker; Barry I Joffe; Victor R Gordeuk; A Patrick MacPhail
Journal:  Endocrine       Date:  2003-08       Impact factor: 3.633

Review 4.  Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?

Authors:  Marco Cosentino; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-17       Impact factor: 4.147

Review 5.  Central nervous system plus autonomic nervous system disorders responsible for gastrointestinal and pancreatobiliary diseases.

Authors:  Fuad Lechin; Bertha van der Dijs
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

6.  [Altered function of the hypothalamic-pituitary-adrenal axis in patients with acute, chronic and episodic pain].

Authors:  M Strittmatter; O Bianchi; D Ostertag; M Grauer; C Paulus; C Fischer; S Meyer
Journal:  Schmerz       Date:  2005-04       Impact factor: 1.107

7.  Enhancement of Anxiety and Modulation of TH and pERK Expressions in Amygdala by Repeated Injections of Corticosterone.

Authors:  Heena Lim; Soyong Jang; Yeonju Lee; Sohyeon Moon; Jieun Kim; Seikwan Oh
Journal:  Biomol Ther (Seoul)       Date:  2012-07       Impact factor: 4.634

8.  The relationship between brown adipose tissue activity and neoplastic status: an (18)F-FDG PET/CT study in the tropics.

Authors:  Yung-Cheng Huang; Tai-Been Chen; Chien-Chin Hsu; Shau-Hsuan Li; Pei-Wen Wang; Bi-Fang Lee; Ching-Yuan Kuo; Nan-Tsing Chiu
Journal:  Lipids Health Dis       Date:  2011-12-20       Impact factor: 3.876

9.  Behavioral inhibition in rhesus monkeys (Macaca mulatta) is related to the airways response, but not immune measures, commonly associated with asthma.

Authors:  Katie Chun; Lisa A Miller; Edward S Schelegle; Dallas M Hyde; John P Capitanio
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.